10X GENOMICS (Germany) Today
| 1KJ Stock | EUR 14.11 0.49 3.36% |
Performance0 of 100
| Odds Of DistressLess than 25
|
10X GENOMICS is trading at 14.11 as of the 27th of November 2024. This is a 3.36% down since the beginning of the trading day. The stock's lowest day price was 14.11. 10X GENOMICS has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for 10X GENOMICS DL are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. The company has 95.6 M outstanding shares. More on 10X GENOMICS DL
Moving together with 10X Stock
Moving against 10X Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
10X Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. 10X GENOMICS's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding 10X GENOMICS or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Serge Saxonov |
| Business Concentration | Health Information Services, Healthcare (View all Sectors) |
10X GENOMICS DL (1KJ) is traded on Frankfurt Exchange in Germany and employs 1,243 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.23 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate 10X GENOMICS's market, we take the total number of its shares issued and multiply it by 10X GENOMICS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. 10X GENOMICS DL classifies itself under Healthcare sector and is part of Health Information Services industry. The entity has 95.6 M outstanding shares.
10X GENOMICS DL has accumulated about 621.96 M in cash with (219.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66.
Check 10X GENOMICS Probability Of Bankruptcy
Ownership Allocation10X GENOMICS holds a total of 95.6 Million outstanding shares. The majority of 10X GENOMICS DL outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 10X GENOMICS DL to benefit from reduced commissions. Hence, institutional investors are subject to a different set of regulations than regular investors in 10X GENOMICS. Please pay attention to any change in the institutional holdings of 10X GENOMICS DL as this could imply that something significant has changed or is about to change at the company. Also note that nearly two million sixty-four thousand eight hundred eighty invesors are currently shorting 10X GENOMICS expressing very little confidence in its future performance.
Check 10X Ownership Details
10X GENOMICS DL Risk Profiles
Although 10X GENOMICS's alpha and beta are two of the key measurements used to evaluate 10X GENOMICS's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.65 | |||
| Standard Deviation | 5.33 | |||
| Variance | 28.39 | |||
| Risk Adjusted Performance | (0.05) |
10X Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in 10X GENOMICS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
10X GENOMICS Corporate Management
Elected by the shareholders, the 10X GENOMICS's board of directors comprises two types of representatives: 10X GENOMICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 10X. The board's role is to monitor 10X GENOMICS's management team and ensure that shareholders' interests are well served. 10X GENOMICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 10X GENOMICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mathai Mammen | Independent Director | Profile | |
| Bradford Crutchfield | Chief Commercial Officer | Profile | |
| Jean Philibert | Chief People Officer | Profile | |
| Benjamin Hindson | President Co-Founder, Chief Scientific Officer, Director | Profile | |
| Brad Crutchfield | Chief Commercial Officer | Profile | |
| Shehnaaz Suliman | Independent Director | Profile |
Other Information on Investing in 10X Stock
10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.